Skip to main content

Haemonetics Corporation (HAE) Stock Analysis

Recovery setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Medical Devices

Sell if holding. Multiple concerning factors at $57.28: Leverage penalty (D/E 1.5): -1.0; Concentration risk — Supplier: single third-party vendor.

Haemonetics is a global medical technology company with Plasma (39.3%), Hospital (41.5%), and Blood Center (19.2%) segments, selling automated collection systems, disposables, and software to plasma centers, hospitals, and blood collectors. Top 10 customers represent ~42% of net... Read more

$57.28+21.8% A.UpsideScore 5.8/10#11 of 40 Medical Devices
QualityF-score8 / 9FCF yield11.52%
Stop $53.27Target $69.77(analyst − 13%)A.R:R 2.0:1
Analyst target$80.20+40.0%10 analysts
$69.77our TP
$57.28price
$80.20mean
$104

Sell if holding. Multiple concerning factors at $57.28: Leverage penalty (D/E 1.5): -1.0; Concentration risk — Supplier: single third-party vendor. Chart setup: Death cross but MACD improving, RSI 44. Score 5.8/10, moderate confidence.

Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.

Recent Developments — Haemonetics Corporation

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Attractive valuation
Risks
Concentration risk — Supplier: single third-party vendor
Leverage penalty (D/E 1.5): -1.0
Weak growth

Key Metrics

P/E (TTM)15.5
P/E (Fwd)9.8
Mkt Cap$2.6B
EV/EBITDA9.9
Profit Mgn7.3%
ROE12.0%
Rev Growth4.8%
Beta0.53
DividendNone
Rating analysts15

Quality Signals

Piotroski F8/9MoatNarrow

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomertop-10 customers42%
    10-K Item 1: 'In fiscal 2025, our ten largest customers accounted for approximately 42% of our net revenues.'
  • HIGHSuppliersingle third-party vendor
    10-K Item 1A: 'we rely on a single vendor to support several of our business processes, including customer service and support and elements of enterprise technology, procurement, accounting and human resources.'

Material Events(8-K, last 90d)

  • 2026-05-01Item 5.02LOW
    Director Charles J. Dockendorff will not stand for re-election at the 2026 Annual Meeting of Shareholders. Not the result of any disagreement. Will continue serving until the meeting.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Revenue Growth
3.7
Low model confidence on this dimension (33%).
GatesMomentum 5.1<5.5 (soft — BUY_NOW allowed but watch)Death cross (50MA < 200MA)Momentum 5.1>=4.5A.R:R 2.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 80d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
44 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $51.00Resistance $62.18

Price Targets

$53
$70
A.Upside+21.8%
A.R:R2.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Analyst Consensus

Analysts15
Consensus3.9/5
Avg Target$80

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-06 (80d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HAE stock a buy right now?

Sell if holding. Multiple concerning factors at $57.28: Leverage penalty (D/E 1.5): -1.0; Concentration risk — Supplier: single third-party vendor. Chart setup: Death cross but MACD improving, RSI 44. Prior stop was $53.27. Score 5.8/10, moderate confidence.

What is the HAE stock price target?

Take-profit target: $69.77 (+21.8% upside). Prior stop was $53.27. Stop-loss: $53.27.

What are the risks of investing in HAE?

Concentration risk — Supplier: single third-party vendor; Leverage penalty (D/E 1.5): -1.0; Weak growth.

Is HAE overvalued or undervalued?

Haemonetics Corporation trades at a P/E of 15.5 (forward 9.8). TrendMatrix value score: 8.0/10. Verdict: Sell.

What do analysts say about HAE?

15 analysts cover HAE with a consensus score of 3.9/5. Average price target: $80.

What does Haemonetics Corporation do?Haemonetics is a global medical technology company with Plasma (39.3%), Hospital (41.5%), and Blood Center (19.2%)...

Haemonetics is a global medical technology company with Plasma (39.3%), Hospital (41.5%), and Blood Center (19.2%) segments, selling automated collection systems, disposables, and software to plasma centers, hospitals, and blood collectors. Top 10 customers represent ~42% of net revenues; the Plasma segment is concentrated among a limited number of large biopharmaceutical customers. Business processes are outsourced to a single third-party vendor.

Related stocks: GMED (Globus Medical, Inc.) · DXCM (DexCom, Inc.) · PODD (Insulet Corporation) · ZBH (Zimmer Biomet Holdings, Inc.) · ATEC (Alphatec Holdings, Inc.)